Study for painful, highly inflammatory condition initiated b

Galapagos NV has announced it has initiated a phase 3 study with small molecule drug filgotinib in patients with the chronic, highly inflammatory condition, active axial spondyloarthritis(AxSpA).

Related Keywords

Bochum , Nordrhein Westfalen , Germany , Ruhr , Japan , Daniele Dambrosio , Xenofon Baraliakos , University Bochum , Ankylosing Spondylitis Disease Activity Score , Ruhr University Bochum , Danieled Ambrosio , Preclinical Research , Ingredients , Clinical Development , Atient Centricity , Linical Evolution , Pis Active Pharmaceutical Ingredients , Hasei Ii , Phase Iii Iv , Galapagos , Rheumatoid Arthritis , Psoriatic Arthritis , Inflammation , Small Molecule Drugs , Small Molecule ,